TORONTO, ONTARIO--(Marketwired - Aug. 10, 2016) - Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced it has engaged Catalent Inhalation, a division of Catalent Pharma Solutions (Catalent), to begin the manufacturing process for its drug AB569 in preparation for the first human trials involving patients with antibiotic resistant lung infections.
Catalent Inhalation will commence with initial stability and formulation studies, which are both important production milestones in preparing a pharmaceutical product for human trials and eventual drug approval by the U.S. Food and Drug Administration and other health authorities.
Once the stability and formulation work is completed with positive results, Arch will engage Catalent Inhalation to manufacture a supply of AB569 that meets good manufacturing practice (GMP) standards to enable human trials to treat cystic fibrosis and chronic obstructive pulmonary disease patients with chronic bacterial lung infections.
Jonathan Arnold, Vice President and General Manager for Advanced Delivery Technologies commented, "We are pleased to support Arch Biopartners' program from our recently expanded facility in Morrisville, North Carolina, Catalent's Centre of Excellence in the development and manufacture of inhaled dose forms."
Notes for Editors
About Catalent Inhalation
Catalent Inhalation has capabilities, expertise, and state-of-the art facilities to expedite product development, from concept and feasibility studies through all stages of the product life cycle. Whether a single service or a turn-key development solution is required, Catalent leverages decades of experience in development, evaluation, and manufacturing to accelerate programs across multiple inhaled dose forms including pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), nasal sprays, nebulizers and liquid inhalers.
Catalent also provides integrated analytical, particle size engineering and clinical trial supply services.
About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com .
More products. Better treatments. Reliably supplied.™
About AB569
AB569 was invented by Dr. Daniel Hassett, Professor at the University of Cincinnati (UC) College of Medicine, to treat antibiotic resistant bacterial lung infections, which is a significant problem for patients with either CF or COPD. AB569 has been exclusively licensed to Arch by UC.
AB569, as a bactericidal compound, constitutes an innovative potential treatment for dealing with pulmonary bacterial infections that are resistant to traditional antibiotics. AB569 also has the potential to be a treatment for antibiotic resistant urinary tract infections. In pre-clinical studies, AB569 has demonstrated significant ability to kill many types of Gram-negative and Gram-positive bacteria.
About Arch Biopartners
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; MetaMx, which targets elusive brain tumor initiating cells; Metablok, a potential treatment for sepsis and cancer metastasis; and, 'Borg' peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
For more information on Arch Biopartners, other public documents Arch has filed on SEDAR and its technologies including, please visit www.archbiopartners.com .
The Company currently has 53,849,679 common shares outstanding.
Forward-Looking Statements
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
